Business
Statement re Injectables Pres
Statement re Injectables Pres.
About this update from Hikma Pharmaceuticals Plc
[{"type":"text","content":"\n RNS Number : 8400I Hikma Pharmaceuticals Plc 25 November 2008 \n \n \n\n\n\n\n\nHikma Pharmaceuticals PLC - Injectables Presentation\n\nLONDON, 25 November 2008: Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) the fast growing multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of generic and in-licensed pharmaceutical products will today present to investors and analysts on the company's Global Injectables business. A copy of this presentation and an audio replay will be available on the company's website at www.hikma.com.\nThe company will also be attending the HSBC European Healthcare Conference in London on the 26th of November. A copy of this presentation will also be available on the company's website.\n- ENDS -\n\n\nEnquiries:\n\n\n\n\nHikma Pharmaceuticals PLC\n\n\n\n\n\n\n\nSusan Ringdal\nInvestor Relations Director\n\n\n+44 20 7399 2760\n\n\n\n\n\nBrunswick\n\n\n\n\n\n\n\nJon Coles/Justine McIlroy\n\n\n+44 20 7404 5959\n\n\n\n\n\nAbout Hikma\nHikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed pharmaceutical products. Hikma's operations are conducted through three businesses: 'Branded', 'Injectables' and 'Generics'. Hikma's operations are based principally in the Middle East and North Africa ('MENA') region, where it is a market leader and sells across 17 countries, the United States and Europe. In 2007, the Group achieved revenues of $449 million and profit attributable to shareholders was $63 million. For news and other information, please visit www.hikma.com.\n\n\n\nThis information is provided by RNSThe company news service from the London Stock Exchange END STRMGMZMGDNGRZZ \n ","length":3902,"tagName":"div"}]